No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
- DOI
- 10.1177/17562864211042458
- Published
- 2021
- Container
- Therapeutic advances in neurological disorders
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17562864211042458,
title = {No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).},
author = {Butzkueven H and Kappos L and Spelman T and Trojano M and Wiendl H and Su R and Liao S and Hyde R and Licata S and Ho PR and Campbell N},
year = {2021},
journal = {Therapeutic advances in neurological disorders},
doi = {10.1177/17562864211042458},
url = {https://doi.org/10.1177/17562864211042458}
}RIS
TY - JOUR TI - No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). AU - Butzkueven H AU - Kappos L AU - Spelman T AU - Trojano M AU - Wiendl H AU - Su R AU - Liao S AU - Hyde R AU - Licata S AU - Ho PR AU - Campbell N PY - 2021 JO - Therapeutic advances in neurological disorders DO - 10.1177/17562864211042458 UR - https://doi.org/10.1177/17562864211042458 ER -
APA
H, B., L, K., T, S., M, T., H, W., R, S., S, L., R, H., S, L., PR, H., & N, C. (2021). No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).. Therapeutic advances in neurological disorders. https://doi.org/10.1177/17562864211042458
Source records
- pubmed · retrieved 2026-09-26T07:55:47.498Z
- europe-pmc · retrieved 2026-09-26T07:55:47.506Z
- doaj · retrieved 2026-09-26T07:55:47.495Z